Russia's single-dose Sputnik Light Covid vaccine okayed in Mauritius

Earlier, Sputnik Light vaccine was also approved for use in the Palestinian territories, according to RDIF.

Sputnik Light
ANI Asia
2 min read Last Updated : Jun 02 2021 | 3:38 PM IST

The Russian Direct Investment Fund (RDIF) on Wednesday announced the approval of the Russian single-dose Sputnik Light COVID-19 vaccine by the Mauritius Health Ministry.

According to a statement by the RDIF, Sputnik Light is the first component of the Sputnik V vaccine. Sputnik Light has demonstrated 79.4 per cent efficacy according to analyzed data taken from 28 days after the injection was administered.

The data was obtained from Russians vaccinated with a single injection, having not received the second one for any reason during the mass vaccination program between December 5, 2020 and April 15 this year.

Mauritius had approved the use of Sputnik V vaccine for emergency use authorisation in March.

"Authorization of Sputnik Light will add a safe and effective COVID vaccine to Mauritius's national portfolio. The vaccine is created on a proven adenoviral vectors platform and enables vaccination of large populations groups more quickly thus creating a herd immunity in a short period," said Kirill Dmitriev, RDIF CEO.

Earlier, Sputnik Light vaccine was also approved for use in the Palestinian territories, according to RDIF.

In a statement on Monday, the RDIF announced the approval of the Russian single-dose Sputnik Light vaccine against coronavirus by the Ministry of Health of the State of Palestine.

The Sputnik Light vaccine has received authorization for use in Russia, according to the Russian Ministry of Health, the Gamaleya National Research Center of Epidemiology and Microbiology and the RDIF.

On February 21, the Gamaleya Center and RDIF launched a global efficacy study of Sputnik Light. The Phase III clinical study involving 7,000 people was conducted in multiple countries including Russia, the UAE and Ghana.

The RDIF said the Sputnik Light vaccine is based on a well-studied human adenoviral vector platform that has proven to be safe and effective. As of May 5, more than 20 million people globally have received the first injection of the Sputnik V vaccine, containing the first component.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineCoronavirus Tests

First Published: Jun 02 2021 | 3:33 PM IST

Next Story